How the hunger for a new weight loss drug is feeding an industry of fakes

Lisa King has been using a counterfeit version of retatrutide since July and, at one point, while also attending the gym and maintaining a healthy diet, she was losing 3 kg (6 lb) per week. She believes the substance is also helping her manage some symptoms of polyendocrine metabolic ovarian syndrome (PMOS). GLP‑1 receptor agonists are known to regulate blood sugar, and several studies indicate that weight‑loss drugs of this class may alleviate issues linked to PMOS, such as severe fatigue, kidney complications and elevated blood pressure. "I'm not definite if it's owed to reta," Lisa says, "but my sweetener cravings person gone down, my periods person regulated and I've got a batch much energy." When asked whether the experimental status of retatrutide concerns her, she replied, "No," she says, "not astatine all. There are galore things that person not been approved." She added, "If I commencement to acquisition immoderate antagonistic broadside effects I'll conscionable travel consecutive disconnected it." Other individuals using illicit retatrutide have reported a range of adverse effects, including brain fog, nausea, diarrhoea, loss of libido and an inability to experience happiness or joy. Medical professionals are expressing growing concern over the side effects observed among users of these counterfeit weight‑loss products. Dr Sahira Dar, a general practitioner and chair of the British Islamic Medical Association, urged healthcare providers to ask about black‑market substances "without judgement" so patients feel able to "disclose what they person taken." Eli Lilly has been developing retatrutide for approximately ten years and is now working to protect its product and halt the illegal sales occurring worldwide. The company says it is taking action against peptide manufacturers, influencers, compounding pharmacies that produce the fake drug, and wellness clinics. It has reported more than 14,000 websites, advertisements and social‑media posts that it claims are illegally selling the medication. Eli Lilly states it "continues to enactment with instrumentality enforcement and regulatory authorities to combat achromatic marketplace drugs." A spokesperson told the BBC: "Any retatrutide disposable online is unapproved, unverified and simply not worthy the risk." The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has carried out raids and made several seizures of "products claiming to incorporate retatrutide" over the past year. The agency notes there are various routes by which these products enter the UK and says it is working to "disrupt amerciable importation and distribution." Nevertheless, the illicit trade persists. Professor O'Shea emphasized that while it is important to "shine a airy connected the dangers of specified achromatic marketplace drugs," the therapeutic value of GLP‑1 based medications should not be dismissed. "GLP-1s are a large beforehand successful managing obesity, a large beforehand successful our penetration into however the encephalon regulates cravings and appetite," he said. "That," he adds, "is huge." At present, retatrutide remains unavailable through legal channels. Eli Lilly intends to submit its application for US FDA approval early next year. The review process could take up to a year, meaning the drug would not be legally obtainable in the United States before the end of 2027 at the earliest. In the United Kingdom, depending on MHRA approval, it could reach the market by 2028.